Hyperliquid Strategies posts $165 million net loss for nine months ended March 31 as HYPE treasury grows
Summary
Hyperliquid Strategies Inc. reported a $165.4 million net loss for the nine months ending March 31, driven by unrealized losses on its HYPE holdings, a one-time write-off from its merger with Sonnet BioTherapeutics, and increased deferred tax expenses. Despite the loss, the firm has aggressively expanded its HYPE treasury to 20 million tokens, supported by $103 million in cash reserves and new staking revenue. CEO David Schamis highlighted the company’s strategic transition away from legacy biotechnology operations toward becoming a capital-efficient vehicle for HYPE exposure.
(Source:The Block)